Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Asthma
Interventions: AZD4604, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more

Conditions: Lymphoma
Interventions: aldesleukin, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: Physical activity intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 69 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder
Interventions: High Dose Buprenorphine, Standard Buprenorphine Dose; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Bilevel positive airway pressure (BiPAP); Device
Lead sponsor: Philips Respironics; Industry
Eligibility: Up to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 62
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Solid Tumors, Cancer
Interventions: HR PEM Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Intensity Interval Exercise (HIIE), Pain Perception, Wisconsin Card Sorting Task
Interventions: Exercise, Cognitive Task; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Interventions: BBI-355, Erlotinib, Futibatinib, BBI-825; Drug
Lead sponsor: Boundless Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more

Conditions: C. Difficile
Interventions: Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Frailty
Interventions: High Intensity Walking; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 60 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Genomic and Histological Evaluation; Genetic
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions: SGR-1505; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Oral rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more

Conditions: Cardiovascular Diseases, Statin Adverse Reaction
Interventions: Bempedoic acid 180 mg tablet, Matching placebo tablet; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 13,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 304
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more

Conditions: Anal High Grade Squamous Intraepithelial Lesion
Interventions: Curcuminoid Capsules; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 30 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, ADT, Relugolix; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 32
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more

Conditions: Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Hematologic Malignancy, Myelodysplastic Syndrome (MDS), Aplastic Anemia
Interventions: haplo/cord transplant; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: Up to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes
Interventions: Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia), Usual care, after system-side dissemination of HOAP; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Physical Performance
Interventions: Aquatic Based Exercise, Land Based Exercise; Other
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Anxiety Disorders, Stress Disorders, Post-Traumatic, Pregnancy, High Risk, Depressive Disorder, Major, Pregnancy Complications, ADHD - Attention Deficit Disorder With Hyperactivity
Interventions: Collaborative Mental Health Care Program (CMHCP); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy; Radiation · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy, Iron Overload, Liver Fat
Interventions: Non-contrast MRI with novel MRI software; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Microbiome, Exercise Tracking Study: Among Individuals at High Risk for Colorectal Cancer

High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)

High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

Acute Effects of High Intensity Interval Exercise on Executive Function

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

Non-Invasive Biomarkers in Prostate Cancer Disease Management

Study of SGR-1505 in Mature B-Cell Neoplasms

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Safety of Anal Curcumin

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients

Comparing Land-based and Aquatic Reduced Exertion High Intensity Interval Training in Sedentary Young Adults

MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

Fully Automated High-Throughput Quantitative MRI of the Liver